Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis.
CONCLUSIONS: CT-naïve patients treated with AA obtained a better clinical benefit in terms of effectiveness, safety and cost-effectiveness ratio than post-CT patients. The effectiveness outcomes were poorer than those reported previously in the clinical trial setting.
PMID: 30022386 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Koninckx M, Marco JL, Pérez I, Faus MT, Alcolea V, Gómez F Tags: Clin Transl Oncol Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hypertension | Prostate Cancer | Study